drugset / Trial / NCT03300947
Psilocybin for Treatment of Obsessive Compulsive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Timeline
- Start
- 2019-01-02
- Primary completion
- 2023-10-30
- Completion
- 2023-12-30
Publications
- Results Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735-40. doi: 10.4088/jcp.v67n1110.
- Moreno FA, Allen KE, Wiegand CB, Dunne R, Prickett JI, Bayze B, Allen JJB. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. J Psychopharmacol. 2026 May;40(5):837-849. doi: 10.1177/02698811261424214. Epub 2026 Mar 13.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lorazepam | Small molecule | 1 mg | — |
| Subject | Psilocybin | Other / unclassified | 100 ug/kg | — |
| Subject | Psilocybin | Other / unclassified | 300 ug/kg | — |